|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 409 12th Street, SW |
Address2 |
|
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
|
5. Senate ID# 400578740-12
|
||||||||
|
6. House ID# 412490000
|
||||||||
| TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Kira Peterson |
Date | 1/17/2025 3:27:45 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Abortion access (general); Access to mifepristone (general); Contraception (general); Maternal mortality and morbidity (general); H.R. 1117, Advancing Safe Medications for Moms and Babies Act; Inclusion of pregnant and lactating individuals in research (general); Obstetric and gynecologic care in rural and underserved areas (general); impact of closures of ob-gyn units in rural hospitals on patient access to care and maternal morbidity and mortality; I H.R. 3305/S. 1606, Black Maternal Health Momnibus Act; H.R. 2569, Doctors of Community (DOC) Act; Teaching Health Center Graduate Medication Education (general); H.R. 3838/S. 2415, Preventing Maternal Deaths Reauthorization Act of 2023; H.R. 3226/S. 1573, PREEMIE Reauthorization Act of 2023; Telemedicine (general); H.R. 5012/S. 2647, SHINE for Autumn Act; S. 712/H.R. 8532, Connected MOM Act; S. 4079/H.R. 8383, Rural Obstetrics Readiness Act; Diversity, Equity, and Inclusion in medicine (general); S. 5236, Keeping Obstetrics Local Act; Implementation of P.L. 117-328, Pregnant Workers Fairness Act; National Health Service Corps (general); H.R. 8037/S. 4147, NIH IMPROVE Act; S. 2840, Bipartisan Primary Care and Health Workforce Act; S. 1840/H.R. 3916, SCREENS for Cancer Act; H.R. 10280, Strengthening Pathways to Health Professions Act; S. 5428/S. 10297, Jeanette Acosta Invest in Womens Health Act; S. 3247/H.R. 6298 Stop Shackling and Detaining Pregnant Women Act; H.R. 3503, NIH Clinical Trial Diversity Act; S. 3211/H.R. 6025, Healthcare Workforce Resilience Act; H.R. 3633, PREVENT HPV Cancers Act; S. 1409/H.R. 7891, Kids Online Safety Act; Patient-physician relationship (general); Alliance for Innovation on Maternal Health; Residency programs in obstetrics and gynecology (general); Abortion training in obstetrics and gynecology residency programs (general); Obstetrician-gynecologist workforce (general); Reproductive health data privacy (general); Substance use disorder during pregnancy (general); Maternal mental health (general); Coverage for infertility (general); Protections for in vitro fertilization (general); HPV vaccination (general); RSV vaccination (general); NIH restructuring (general); NICHD Strategic Plan (general); physician liability (general); Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC) recommendations (general); NIH/NICHD womens health research (general);; human milk in NICUs; Executive Order 13952; EMTALA implementation (general); Medicare conditions of participation regarding opioids; Paid leave for patients who experience a stillbirth; menthol cigarettes and flavored cigars; nicotine limits in cigarettes; National Strategic Plans for HIV/AIDS, STIs, Vaccines and Viral Hepatitus; environmental health curriculum in medical school; heat-related deaths; hypertension in pregnancy and postpartum; adolescent reproductive health; immediate postpartum LARC; no-cost contraceptive coverage; access to fertility services and treatments; improving postpartum health care visit rates; worksite lactation support programs; newborn nutrition; Levels of Maternal Care; newborn screening; contraceptive and fertility counseling for patients with cancer; access to PrEP; maternal vaccinations; HPV vaccinations; syphilis screening during pregnancy; oral health care during pregnancy; opioid use disorder treatment for pregnant and postpartum individuals.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), White House Office, Executive Office of the President (EOP), Centers For Disease Control & Prevention (CDC), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), Food & Drug Administration (FDA), Government Accountability Office (GAO), Equal Employment Opportunity Commission (EEOC), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rebecca |
Lauer |
|
|
|
Erin |
Alston |
|
|
|
Taylor |
Platt |
|
|
|
Rachel |
Tetlow |
|
|
|
Lillie |
Heyman |
|
|
|
Lisa |
Satterfield |
|
|
|
Sarah |
Bogdan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 2474, Strengthening Medicare for Patients and Providers Act; Physician payment under Medicare (general); Graduate medical education (general); Prior authorization in Medicare (general); Medicaid free choice of provider requirement; Implementation of P.L. 117-328, Consolidated Appropriations Act, including permanent option for postpartum Medicaid extension; Physician reimbursements under Medicaid (general); S. 4532/H.R. 8702, Improving Seniors Timely Access to Care Act telehealth under Medicare, Medicaid, and CHIP (general S.1378/H.R. 5819, COMPLETE Care Act; pay parity between Medicare and Medicaid (general); H.R. 10073, Medicare Patient Access and Practice Stabilization Act of 2024; S. 4935, Physician Fee Stabilization Act; H.R. 6371, Provider Reimbursement Stability Act, Medicare conditions of participation.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rebecca |
Lauer |
|
|
|
Erin |
Alston |
|
|
|
Taylor |
Platt |
|
|
|
Rachel |
Tetlow |
|
|
|
Lillie |
Heyman |
|
|
|
Lisa |
Satterfield |
|
|
|
Sarah |
Bogdan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code IMM
16. Specific lobbying issues
H.R. 4942/S. 665, Conrad State 30 and Physician Access Reauthorization
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Citizenship & Immigration Services (USCIS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rebecca |
Lauer |
|
|
|
Lillie |
Heyman |
|
|
|
Rachel |
Tetlow |
|
|
|
Sarah |
Bogdan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Centers for Disease Control and Prevention (CDC); National Institutes of Health (NIH); Health Resources and Services Administration (HRSA); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Alliance for Innovation on Maternal Health (HRSA); Safe Motherhood and Infant Health Program (CDC); Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC); Teaching Health Center Graduate Medical Education Program; Congressionally Directed Medical Research Program; Defense Health Research Programs; Title X family planning program; CDC Division of Sexually Transmitted Disease Prevention NIH restructuring; Title VII Health Professions and Title VIII Nursing Workforce Development programs; Abortion access (general; Abortion access for servicemembers and veterans; Contraception (general); Medicaid free choice of provider requirement; STI Clinical Resources Demonstration Program; Abortion training for medical residents; H.R. 9029/S. 4942, FY2025 Labor, Health and Human Services, and Education, and Related Agencies appropriations bill; H.R. 9027/S. 4690, FY2025 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill; H.R. 8774/S. 4921, FY2025 Defense appropriations bill; H.R. 8580/S. 4677, FY2025 Military Construction, Veterans Affairs, and Related Agencies appropriations bill
17. House(s) of Congress and Federal agencies Check if None
Centers For Disease Control & Prevention (CDC), Natl Institutes of Health (NIH), U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health Resources & Services Administration (HRSA), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rachel |
Tetlow |
|
|
|
Rebecca |
Lauer |
|
|
|
Lillie |
Heyman |
|
|
|
Sarah |
Bogdan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
Access to maternity care for servicemembers and dependents (general); coverage of in vitro fertilization under TRICARE; coverage of fertility preservation services under TRICARE ; H.R. 8070, Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025; S.4638, National Defense Authorization Act for Fiscal Year 2025; gender-affirming care for minors under TRICARE
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rachel |
Tetlow |
|
|
|
Rebecca |
Lauer |
|
|
|
Lillie |
Heyman |
|
|
|
Sarah |
Bogdan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CON
16. Specific lobbying issues
Ratification of the Equal Rights Amendment
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, Executive Office of the President (EOP), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rebecca |
Lauer |
|
|
|
Rachel |
Tetlow |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |